Table 1. In Vivo Antiviral Activity of the Target Compounds against TMV at 500 μg/mL.

	inhibition rate (%)a
compounds	curative activity	protection activity	inactivation activity
6a	38.6 ± 1.9	35.4 ± 2.1	34.7 ± 2.6
6b	43.4 ± 3.0	38.9 ± 1.7	42.3 ± 3.2
6c	27.3 ± 2.2	51.4 ± 0.8	58.6 ± 2.1
6d	58.2 ± 1.5	47.5 ± 1.5	50.2 ± 2.0
6e	34.9 ± 3.1	56.5 ± 1.3	62.9 ± 3.2
6f	58.8 ± 2.8	47.5 ± 3.3	69.8 ± 2.8
6g	45.3 ± 2.3	54.4 ± 2.6	70.2 ± 3.3
6h	40.5 ± 3.1	58.8 ± 1.3	78.0 ± 1.9
6i	50.6 ± 1.5	43.5 ± 2.0	52.5 ± 2.5
6j	49.5 ± 3.2	46.8 ± 2.4	64.4 ± 1.5
6k	48.3 ± 2.5	50.0 ± 2.2	60.3 ± 2.1
6L	46.8 ± 2.2	39.3 ± 3.1	38.6 ± 1.8
6m	50.6 ± 1.0	46.2 ± 1.4	47.2 ± 3.3
6n	36.3 ± 2.2	55.5 ± 1.2	62.3 ± 2.7
6o	29.3 ± 1.7	49.4 ± 1.3	54.9 ± 1.6
6p	47.3 ± 1.5	64.2 ± 1.2	72.1 ± 2.0
6q	43.1 ± 3.6	59.5 ± 1.3	70.2 ± 1.2
6r	61.3 ± 2.6	55.7 ± 1.3	73.2 ± 1.5
6s	55.3 ± 1.0	68.7 ± 2.6	76.9 ± 1.2
6t	43.2 ± 0.6	61.3 ± 1.3	80.0 ± 1.1
6u	45.8 ± 1.9	39.5 ± 1.8	47.3 ± 2.9
6v	39.4 ± 1.4	22.0 ± 2.7	43.2 ± 2.8
6w	49.3 ± 1.1	43.8 ± 0.9	49.6 ± 1.2
6x	54.5 ± 2.2	49.9 ± 1.4	68.7 ± 1.2
6y	51.9 ± 3.1	54.2 ± 1.2	64.3 ± 2.5
Ningnanmycin	56.4 ± 1.5	66.4 ± 2.0	94.0 ± 1.5

^aThe mean value derived from three repeated measurements.